6ZB0
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH 1-benzyl-N-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide
This is a non-PDB format compatible entry.
Summary for 6ZB0
| Entry DOI | 10.2210/pdb6zb0/pdb |
| Descriptor | Bromodomain-containing protein 2, 1,2-ETHANEDIOL, ~{N}-methyl-2-oxidanylidene-1-(phenylmethyl)pyridine-3-carboxamide, ... (5 entities in total) |
| Functional Keywords | inhibitor, histone, epigenetic reader, bromodomain, brd2, bromodomain containing protein 2, antagonist, transcription |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 1 |
| Total formula weight | 13932.04 |
| Authors | Chung, C. (deposition date: 2020-06-06, release date: 2020-08-05, Last modification date: 2024-05-01) |
| Primary citation | Seal, J.T.,Atkinson, S.J.,Aylott, H.,Bamborough, P.,Chung, C.W.,Copley, R.C.B.,Gordon, L.,Grandi, P.,Gray, J.R.J.,Harrison, L.A.,Hayhow, T.G.,Lindon, M.,Messenger, C.,Michon, A.M.,Mitchell, D.,Preston, A.,Prinjha, R.K.,Rioja, I.,Taylor, S.,Wall, I.D.,Watson, R.J.,Woolven, J.M.,Demont, E.H. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. J.Med.Chem., 63:9093-9126, 2020 Cited by PubMed Abstract: The profound efficacy, yet associated toxicity of pan-BET inhibitors is well documented. The possibility of an ameliorated safety profile driven by significantly selective (>100-fold) inhibition of a subset of the eight bromodomains is enticing, but challenging given the close homology. Herein, we describe the X-ray crystal structure-directed optimization of a novel weak fragment ligand with a pan-second bromodomain (BD2) bias, to potent and highly BD2 selective inhibitors. A template hopping approach, enabled by our parallel research into an orthogonal template (, GSK046), was the basis for the high selectivity observed. This culminated in two tool molecules, (GSK620) and (GSK549), which showed an anti-inflammatory phenotype in human whole blood, confirming their cellular target engagement. Excellent broad selectivity, developability, and in vivo oral pharmacokinetics characterize these tools, which we hope will be of broad utility to the field of epigenetics research. PubMed: 32702236DOI: 10.1021/acs.jmedchem.0c00796 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.613 Å) |
Structure validation
Download full validation report
